This includes the design of universal CAR T cells with reduced potential for both initiating graft-versus-host disease (GVHD) and eliciting donor T-cell rejection, through targeted disruption of the endogenous T-cell receptor (TRAC) and beta-2 microglobulin (B2M), respectively [7, 8]. This evidence concerns the gene TRAC and graft versus host disease.